Inhibitor-based affinity probes for the investigation of JAK signaling pathways

Proteomics

Volumn 15, Issue 17, 2015, Pages 3066-3074

  Höfener, Michael ^a   Pachl, Fiona ^b   Kuster, Bernhard ^b,c   Sewald, Norbert ^a  

^a BIELEFELD UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Munich Center for Integrated Protein Science   (Germany)

Author keywords

Animal proteomics; Chemical proteomics; JAK signaling; Kinase; Mass spectrometry; Selectivity profiling

Indexed keywords

JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGENIC AGENT; MOMELOTINIB; BENZAMIDE DERIVATIVE; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; MOLECULAR PROBE; N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE; PROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN KINASE TYK2; PYRIMIDINE DERIVATIVE; TYK2 PROTEIN, HUMAN;

ARTICLE; DRUG PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN ANALYSIS; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR DOCKING; MOLECULAR PROBE; PHARMACOLOGY; SIGNAL TRANSDUCTION; SYNTHESIS;

BENZAMIDES; CELL LINE; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MOLECULAR DOCKING SIMULATION; MOLECULAR PROBES; PROTEIN KINASE INHIBITORS; PROTEINS; PYRIMIDINES; SIGNAL TRANSDUCTION; TYK2 KINASE;

EID: 84940587304     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400324     Document Type: Article

References (44)

1. O'Shea, J. J., Gadina, M., Schreiber, R. D., Cytokine signaling in 2002: new surprises in the JAK/STAT pathway. Cell 2002, 109, 121-131.
2. Aaronson, D. S., Horvath, C. M., A road map for those who don't know JAK-STAT. Science 2002, 296, 1653-1655.
3. Xu, D., Qu, C.-K., Protein tyrosine phosphatases in the JAK/STAT pathway. Front. Biosci. 2008, 13, 4925-4932.
4. Murray, P. J., The JAK-STAT signaling pathway: input and output integration. J. Immunol. 2007, 178, 2623-2629.
5. Stark, G. R., Darnell Jr., J. E., The JAK-STAT pathway at twenty. Immunity 2012, 36, 503-514.
6. Sansone, P., Bromberg, J., Targeting the interleukin-6/Jak/Stat pathway in human malignancies. J. Clin. Oncol. 2012, 30, 1005-1014.
7. Grandvaux, N., Servant, M. J., tenOever, B., Sen, G. C. et al., Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J. Virol. 2002, 76, 5532-5539.
8. Liu, Y., Liu, H., Meyer, C., Li, J. et al., Transforming growth factor-β (TGF-β)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation. J. Biol. Chem. 2013, 288, 30708-30719.
9. Harrison, D. A., The JAK/STAT pathway. Cold Spring Harb. Perspect. Biol. 2012, 4, a011205.
10. Papp, K. A., Menter, A., Strober, B., Langley, R. G. et al., Efficacy and safety of tofacitinib, an oral Janus Kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br. J. Dermatol. 2012, 167, 668-677.
11. Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshouri, O. T. et al., Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012, 489, 155-159.
12. Toms, A. V., Deshpande, A., McNally, R., Jeong, Y. et al., Structure of a pseudokinase-domain switch that controls oncogenic activation of JAK kinases. Nat. Struct. Mol. Biol. 2013, 20, 1221-1223.
13. Yoshikawa, H., Matsubara, K., Qian, G.-S., Jackson, P. et al., SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 2001, 28, 29-35.
14. Brady, J. J., Li, M., Suthram, S., Jiang, H. et al., Early role for IL-6 signalling during generation of induced pluripotent stem cells revealed by heterokaryon RNA-Seq. Nat. Cell Biol. 2013, 15, 1244-1252.
15. Nicolas, C. S., Peineau, S., Amici, M., Csaba, Z. et al., The JAK/STAT pathway is involved in synaptic plasticity. Neuron 2012, 73, 374-390.
16. Rawlings, J. S., Rosler, K. M., Harrison, D. A., The JAK/STAT signaling pathway. J. Cell Sci. 2004, 117, 1281-1283.
17. Gygi, S. P., Corthals, G. L., Zhang, Y., Rochon, Y. et al., Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc. Natl. Acad. Sci. U S A 2000, 97, 9390-9395.
18. Schirle, M., Bantscheff, M., Kuster, B., Mass spectrometry-based proteomics in preclinical drug discovery. Chem. Biol. 2012, 19, 72-84.
19. Godl, K., Wissing, J., Kurtenbach, A., Habenberger, P. et al., An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. U S A 2011, 100, 15434-15439.
20. Bantscheff, M., Drewes, G., Chemoproteomic approaches to drug target identification and drug profiling. Bioorg. Med. Chem. 2012, 20, 1973-1978.
21. Rix, U., Superti-Furga, G., Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 2009, 5, 616-624.
22. Hagenstein, M. C., Mussgnug, J. H., Lotte, K., Plessow, R. et al., Affinity-based tagging of protein families with reversible inhibitors. Angew. Chem. Int. Ed. Engl. 2003, 42, 5635-5638.
23. Hagenstein, M. C., Sewald, N., Chemical tools for activity-based proteomics. J. Biotechnol. 2006, 124, 56-73.
24. Brehmer, D., Greff, Z., Godl, K., Blencke, S. et al., Cellular targets of gefitinib. Cancer Res. 2005, 65, 379-382.
25. Li, J., Rix, U., Fang, B., Bai, Y. et al., A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol. 2010, 6, 291-299.
26. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S. et al., Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 2007, 25, 1035-1044.
27. Pachl, F., Plattner, P., Ruprecht, B., Médard, G. et al., Charcterization of a chemical affinity probe targeting Akt kinases. J. Proteome Res. 2013, 12, 3792-3800.
28. Fleischer, T. C., Murphy, B. R., Flick, J. S., Terry-Lorenzo, R. T. et al., Chemical proteomics identifies Nampt as the Target of CB30865, an orphan cytotoxic compound. Chem. Biol. 2010, 17, 659-664.
29. Kruse, U., Pallasch, C. P., Bantscheff, M., Eberhard, D. et al., Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia 2011, 25, 89-100.
30. Höfener, M., Pachl, F., Take, T., Fischer von Mollard, G. et al., Investigating RET-RTK signaling pathways using an IAP-based activity-profiling approach. J. Proteome Res. 2014, 13, 3628-3634.
31. Trott, O., Olson, A. J., AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2009, 31, 455-461.
32. Shevchenko, A., Wilm, M., Vorm, O., Mann, M., Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal. Chem. 1996, 68, 850-858.
33. Hauck, S. M., Dietter, J., Kramer, R. L., Hofmaier, F. et al., Deciphering membrane-associated molecular processes in target tissue of autoimmune uveitis by label-free quantitative mass spectrometry. Mol. Cell. Proteomics 2010, 9, 2292-2305.
34. Flanagan, M. E., Blumenkopf, T. A., Brissette, W. H., Brown, M. F. et al., Discovery of CP-690550: a potent and selective Janus Kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J. Med. Chem. 2010, 53, 8468-8484.
35. Chrencik, J. E., Patny, A., Leung, I. K., Korniski, B. et al., Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J. Mol. Biol. 2010, 400, 413-433.
36. Gerspacher, M., Furet, P., Vangrevelinghe, E., Pissot Soldermann, C. et al., Quinoxaline Derivatives as inhibitors of the tyrosine kiinase activity of Janus kinases. WO 2008/148867 A3.
37. Pissot-Soldermann, C., Gerspacher, M., Furet, P., Gaul, C. et al., Discovery and SAR of potent, orally available 2, 8-diaryl-quinoxalines as a new class of JAK2 inhibitors. Bioorg. Med. Chem. Lett. 2010, 20, 2609-2613.
38. Burns, C. J., Bourke, D. G., Andrau, L., Bu, X. et al., Phenylaminopyrimidines as inhibitors of Janus Kinases (JAKs). Bioorg. Med. Chem. Lett. 2009, 19, 5887-5892.
39. Forsyth, T., Kearney, P. C., Kim, B. G., Johnson, H. W. B. et al., SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors. Bioorg. Med. Chem. Lett. 2012, 22, 7653-7658.
40. Médard, G., Pachl, F., Ruprecht, B., Klaeger, S. et al., Optimized chemical proteomics assay for kinase inhibitor profiling. J. Proteome Res. 2015, 14, 1574-1586.
41. Pardanani, A., Gotlib, J., Gupta, V., Roberts, A. W. et al., Update on the long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Blood 2013, 122, 108.
42. Lemeer, S., Zörgiebel, C., Ruprecht, B., Kohl, K. et al., Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity. J. Proteome Res. 2013, 12, 1723-1731.
43. Pardanani, A., Lasho, T., Smith, G., Burns, C. J. et al., CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009, 23, 1441-1445.
44. Kipp, R. A., Case, M. A., Wist, A. D., Cresson, C. M. et al., Molecular targeting of inhibitor of apoptosis proteins based on small molecule mimics of natural binding partners. Biochemistry 2002, 41, 7344-7349.